摘要
目的:探讨风湿性心脏瓣膜病合并心房颤动(AF)患者心肌组织中组蛋白-赖氨酸N-甲基转移酶EZH2与α-平滑肌肌动蛋白(α-SMA)的表达变化研究。方法:将20例风湿性心脏瓣膜病接受瓣膜置换手术患者,于体外循环前切取的右心耳组织作为研究对象,分为两组:AF组(n=10)和窦性心律(SR)组(n=10),分别应用Masson染色观察心肌组织中胶原沉积情况,应用免疫组化、qRT-PCR、Western blot法检测心肌组织中EZH2与α-SMA表达变化。结果:Masson染色提示AF组与SR组相比,AF组中胶原沉积明显增多,胶原容积分数增加(P<0.05);免疫组化检测显示AF组与SR组相比,AF组EZH2与α-SMA蛋白表达增加(P<0.05)。同时,Western blot检测显示AF组与SR组相比,AF组EZH2与α-SMA蛋白表达增加(P<0.05)。qRT-PCR显示AF组与SR组相比,AF组EZH2与α-SMA mRNA表达增加(P<0.05)。结论:EZH2与α-SMA在房颤组织中高表达,提示EZH2与α-SMA可能促进风湿性心脏瓣膜病合并心房颤动发生发展。
AIM:To investigate the expression correlation between histone-lysine N-methyltransferase EZH2 andα-SMA in the patients with rheumatic heart disease and atrial fibrillation(AF).METHODS:Tissues of auricula dextra were removed from 20 patients with rheumatic heart disease undergoing cardiac surgery for correction to valvular defect.According to the definition of AF,20 patients were divided into group of AF group and of sinus rhythm(SR)group(n=10).The collagen deposition in myocardial tissue was detected by Masson's trichrome stain.The expression of EZH2 andα-SMA were detected by immunohistochemistry,qRT-PCR and Western blot.RESULTS:Masson staining results revealed that the collagen deposition and the comparisons of CVF were significantly increased in the AF heart tissue compared with the SR control(P<0.05).Immunohistochemistry indicated that comparing with the SR group;the expressions of EZH2 andα-SMA protein were significantly increased in AF group(P<0.05).Western blot indicated that compared with the SR group,the expressions of EZH2 andα-SMA protein were significantly increased in AF group(P<0.05).Moreover,qRT-PCR found that compared with the SR group,the expressions of EZH2 andα-SMA mRNA were significantly increased in AF group(P<0.05).CONCLUSION:High expressions of EZH2 andα-SMA indicate EZH2 andα-SMA can regulate the development of AF.
作者
徐盛松
陶辉
石开虎
丁季飞
XU Shengsong;TAO Hui;SHI Kaihu;DING Jifei(Department of Cardiothoracic Surgery, the Second Affiliated Hospital of Anhui Medical University , Cardiovascular Disease Research Center of Anhui Medical University, Hefei 230601, Anhui, China)
出处
《中国临床药理学与治疗学》
CAS
CSCD
2019年第12期1371-1375,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家自然科学基金项目(81570295)
安徽省自然科学基金项目(1808085MH231)